Mission Therapeutics
Mission Therapeutics is a clinical-stage biotech company developing first-in-class therapeutics that enhance mitophagy to promote cell and organ health. Their lead drug candidates, MTX325 and MTX652, inhibit USP30 to increase mitochondrial ubiquitylation, improving cellular health and potentially treating diseases linked to dysfunctional mitochondria.
Funding Round:
Funding Amount: £25.2M
Date: 14-Mar-2024
Investors: Pfizer Venture Investments, Sofinnova Partners, Roche Venture Fund, SR One, IP Group, Rosetta Capital
Markets: Biotechnology, Pharmaceuticals, Healthtech, Oncology, Neurodegeneration
HQ: Cambridge, Cambridgeshire, United Kingdom
Founded: 2011
Website: https://www.missiontherapeutics.com/
LinkedIn: https://uk.linkedin.com/company/mission-therapeutics
Twitter: https://twitter.com/MISSIONTherapeu
Crunchbase: https://www.crunchbase.com/organization/mission-therapeutics
Leave a Comment
Comments
No comments yet.